{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Number of subjects who had treatment (AFM13) and developed anti-drug antibodies (ADA).","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety set consisted of all subjects who received at least one dose of AFM13and had at least one post-baseline safety assessment.","reportingStatus":"POSTED","timeFrame":"Pre-dose Day 1 on cycle 1 and end of treatment, up to approximately 46 months.","title":"Number of Subjects Who Developed Anti-drug Antibodies (ADA) During Treatment","type":"SECONDARY","unitOfMeasure":"Participants"}